Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery

European Urology Open Science - Tập 40 - Trang 117-124 - 2022
Nicolai Huebner1,2, Sazan Rasul3, Pascal Baltzer4, Paola Clauser4, Karl Hermann Grubmüller5, Markus Mitterhauser3,6, Marcus Hacker3, Axel Heidenreich7, Paweł Rajwa8,1, Harun Fajković1,9,2, Shahrokh F. Shariat10,1,11,12,13,9, Bernhard Grubmüller1,2
1Department of Urology, Medical University of Vienna, Vienna, Austria
2Working Group for Diagnostic imaging in Urology (ABDU), Austrian association of Urology (ÖGU), Vienna, Austria
3Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
4Department of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria
5Department of Urology and Andrology, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria
6Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
7Department of urology, Uro-oncology, Robot-Assisted and Specialized Surgery, University of Cologne, Cologne, Germany
8Department of Urology, Medical University of Silesia, Zabrze, Poland
9Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
10Department of Urology and Division of Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA
11Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
12Department of Urology, University of Texas Southwestern, Dallas, TX, USA
13Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Kopp, 2020, (68)Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy, World J Urol, 38, 3085, 10.1007/s00345-020-03131-0

Grubmüller, 2018, PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact, Clin Cancer Res, 24, 6300, 10.1158/1078-0432.CCR-18-0768

Roach, 2018, The Impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study, J Nucl Med, 59, 82, 10.2967/jnumed.117.197160

Grubmüller, 2018, (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy—diagnostic performance and impact on therapeutic decision-making, Eur J Nucl Med Mol Imaging, 45, 235, 10.1007/s00259-017-3858-2

Fendler, 2019, Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer, Clin Cancer Res, 25, 7448, 10.1158/1078-0432.CCR-19-1050

Grubmüller, 2020, Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer, Prostate, 80, 74, 10.1002/pros.23919

Hope, 2021, Diagnostic accuracy of 68Ga-PSMA-11 PET for Pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial, JAMA Oncol, 7, 1635, 10.1001/jamaoncol.2021.3771

Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet (London, England), 395, 1208, 10.1016/S0140-6736(20)30314-7

Cornford, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol, 71, 630, 10.1016/j.eururo.2016.08.002

Calais, 2018, (68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/ml: impact on salvage radiotherapy planning, J Nucl Med, 59, 230, 10.2967/jnumed.117.201749

Abufaraj, 2019, Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy, Eur J Nucl Med Mol Imaging, 46, 2169, 10.1007/s00259-019-04361-0

Maurer, 2016, Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer, J Urol, 195, 1436, 10.1016/j.juro.2015.12.025

Morris, 2018, A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: examination of diagnostic accuracy (OSPREY), J Clin Oncol, 36, TPS5092, 10.1200/JCO.2018.36.15_suppl.TPS5092

Heidenreich, 2018, Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases, Eur Urol Oncol, 1, 46, 10.1016/j.euo.2018.03.002

Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832, 10.1016/j.juro.2014.09.089

Vargas, 2016, Updated Prostate Imaging Reporting and Data System (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference, Eur Radiol, 26, 1606, 10.1007/s00330-015-4015-6

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Harisinghani, 2003, Noninvasive detection of clinically occult lymph-node metastases in prostate cancer, N Engl J Med, 348, 2491, 10.1056/NEJMoa022749

Hovels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022

Giesel, 2019, Detection efficacy of (18)F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy, J Nucl Med, 60, 362, 10.2967/jnumed.118.212233

Hoffmann, 2019, The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer, Oncotarget, 10, 6124, 10.18632/oncotarget.27239

Schwenck, 2019, Intention-to-treat analysis of (68)Ga-PSMA and (11)C-choline PET/CT versus CT for prostate cancer recurrence after surgery, J Nucl Med, 60, 1359, 10.2967/jnumed.118.224543

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Attard, 2022, Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol, Lancet, 399, 447, 10.1016/S0140-6736(21)02437-5

Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Parikh, 2019, Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease, BMC Cancer, 19, 291, 10.1186/s12885-019-5496-5

De Bruycker, 2020, PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial, BMC Cancer, 20, 406, 10.1186/s12885-020-06911-4

Chalouhy, 2019, Current controversies on the role of lymphadenectomy for prostate cancer, Urol Oncol, 37, 219, 10.1016/j.urolonc.2018.11.020

Thông tin
Thông tin xuất bản

European Urology Open Science

Tập 40

117-124

Thông tin tác giả